Last reviewed · How we verify
S. boulardii
S. boulardii is a probiotic yeast that helps maintain a healthy gut microbiome.
S. boulardii is a probiotic yeast that helps maintain a healthy gut microbiome. Used for Treatment of Clostridioides difficile infection, Prevention of antibiotic-associated diarrhea.
At a glance
| Generic name | S. boulardii |
|---|---|
| Also known as | probiotics |
| Sponsor | Muhammad Aamir Latif |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
S. boulardii is a non-pathogenic yeast that adheres to the intestinal mucosa, competing with pathogenic microorganisms for adhesion sites and modulating the immune response. It also produces enzymes that help break down toxins and other substances that can harm the gut lining.
Approved indications
- Treatment of Clostridioides difficile infection
- Prevention of antibiotic-associated diarrhea
Common side effects
- Abdominal pain
- Flatulence
Key clinical trials
- Probiotics in COPD: Effects on Symptoms, Lung Function, and Inflammation (NA)
- Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function (EARLY_PHASE1)
- Effects of Probiotic Consumption in Children With Autism Spectrum Disorder (ASD) (PHASE2)
- Effects of Saccharomyces Boulardii CNCM I-745 on Antibiotic-Associated Perturbation in Children Treated for Acute Respiratory Infections (RESTORE Study) (PHASE4)
- Zinc Plus Saccharomyces Boulardii Versus Zinc Alone in the Treatment of Acute Diarrhea (NA)
- Effect of the Use of Probiotic S. Boulardii on Acute Viral Inflammatory Diarrhea Diagnosed With Multiplex PCR. (NA)
- S. Boulardii in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults With Respiratory Tract Infections (PHASE4)
- Effect of Probiotics on the Fecal Resistome During Helicobacter Pylori Eradication Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S. boulardii CI brief — competitive landscape report
- S. boulardii updates RSS · CI watch RSS
- Muhammad Aamir Latif portfolio CI